We’re in a new phase of the Covid-19 pandemic in which new mutations will have to be consistently monitored — especially as the vaccine race continues. This reality is something I’m always thinking about in my role in financial services supporting health care clients at J.P. Morgan.
How will these mutations affect the business of health care — and how can clients and organizations best prepare — for next month and for the years to come? And how are health care business leaders supposed to model and implement strategies when there exists such a wide range of potential outcomes stemming from new virus variants?
For instance, just as things began to slide back toward normal, the Delta variant came into play. It’s projected to peak in mid-October, with daily deaths more than triple what they are now, based on the Covid-19 Forecast Hub, which combines the results of more than 30 data models. Although vaccines offer significant protection against the Delta variant, public hesitancy to get the vaccine continues to challenge the race against time.
Create a display name to comment
This name will appear with your comment
